| Literature DB >> 26517654 |
Rosemeire Cobo Zanella1, Maria Cristina de Cunto Brandileone1, Ana Lúcia Andrade2, Cinthya Terumi Ogassavara1, Cleiton Eduardo Fiório1, Angela Pires Brandão1, Samanta Cristine Grassi Almeida1, Ana Paula Silva Lemos1, Maria Cecília Gorla1, Telma Regina Carvalhanas3, Helena Sato3, Bernadete Liphaus3, Maria Lígia Nerger4, Monica Conde4, Ana Freitas Ribeiro3.
Abstract
The aim of the present study was to assess the prevalence of Haemophilus influenzae type b (Hib) nasopharyngeal (NP) colonisation among healthy children where Hib vaccination using a 3p+0 dosing schedule has been routinely administered for 10 years with sustained coverage (> 90%). NP swabs were collected from 2,558 children who had received the Hib vaccine, of whom 1,379 were 12-< 24 months (m) old and 1,179 were 48-< 60 m old. Hi strains were identified by molecular methods. Hi carriage prevalence was 45.1% (1,153/2,558) and the prevalence in the 12-< 24 m and 48-< 60 m age groups were 37.5% (517/1,379) and 53.9% (636/1,179), respectively. Hib was identified in 0.6% (16/2,558) of all children in the study, being 0.8% (11/1,379) and 0.4% (5/1,179) among the 12-< 24 m and 48-< 60 m age groups, respectively. The nonencapsulate Hi colonisation was 43% (n = 1,099) and was significantly more frequent at 48-< 60 m of age (51.6%, n = 608) compared with that at 12-< 24 m of age (35.6%, n = 491). The overall resistance rates to ampicillin and chloramphenicol were 16.5% and 3.7%, respectively; the co-resistance was detected in 2.6%. Our findings showed that the Hib carrier rate in healthy children under five years was very low after 10 years of the introduction of the Hib vaccine.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26517654 PMCID: PMC4667578 DOI: 10.1590/0074-02760150140
Source DB: PubMed Journal: Mem Inst Oswaldo Cruz ISSN: 0074-0276 Impact factor: 2.743
Prevalence of Haemophilus influenzae (Hi) nasopharyngeal carriage, Hi types and nonencapsulated Hi (NTHi) by age groups in healthy vaccinated childrena, municipality of São Paulo, Brazil, 2010
| Hi carrier status | Total (n = 2,558) | Age groups
(months) | ||
|---|---|---|---|---|
| 12-< 24 (n = 1,379) | 48-< 60 (n = 1,179) | |||
|
| ||||
| n (%) | n (%) | n (%) | p | |
| Carrier | 1,153 (45.1) | 517 (37.5) | 636 (53.9) | < 0.001 |
|
| ||||
| b | 16 (0.6) | 11 (0.8) | 5 (0.4) | > 0.05 |
| a | 16 (0.6) | 6 (0.4) | 10 (0.8) | > 0.05 |
| c | 3 (0.1) | 1 (0.1) | 2 (0.2) | - |
| d | 3 (0.1) | 1 (0.1) | 2 (0.2) | - |
| e | 15 (0.6) | 7 (0.5) | 8 (0.7) | > 0.05 |
| f | 1 (0) | 0 (0) | 1 (0.1) | - |
| Encapsulate-Hi | 54 (2.1) | 26 (1.9) | 28 (2.4) | > 0.05 |
| NTHi | 1,099 (43) | 491 (35.6) | 608 (51.6) | < 0.001 |
| Non-Hi carrier | 1,405 (54.9) | 862 (62.5) | 543 (46.1) | < 0.001 |
: Hi type b conjugate vaccine.